Vaxcyte, Inc. PCVX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$766.63M-65.2% | -$463.93M-15.3% | -$402.27M-80.0% | -$223.49M-123% | ||
| $16.4M+134% | $7M+122% | $3.16M+11.4% | $2.83M+57.4% | ||
| $138.85M+63.7% | $84.82M+74.0% | $48.76M+106% | $23.65M+120% | ||
| —— | $34.58M+208% | $11.23M+288% | $2.9M+123% | ||
| —— | —— | $37.11M+417% | $7.17M— | ||
| $17.72M— | —— | -$17.87M— | —— | ||
| $8.46M-4.3% | $8.84M+26.0% | $7.02M+6.0% | $6.62M+299% | ||
| —— | $41.89M+271% | $11.28M+880% | $1.15M— | ||
| -$655.58M-44.8% | -$452.63M-52.5% | -$296.79M-74.0% | -$170.6M-40.5% | ||
| $13.71M-38.9% | $22.43M— | —— | $5.84M-10.9% | ||
| $1.21B-60.8% | $3.09B+132% | $1.33B+1,194% | $102.75M-69.5% | ||
| $174.69M+161% | $66.96M+432% | $12.59M-13.1% | $14.48M— | ||
| $437.35M+122% | -$2.01B-152% | -$795.59M— | —— | ||
| $13.01M-93.4% | $195.97M— | —— | $97.3M+600% | ||
| $10.99M-23.1% | $14.29M+269% | $3.88M+350% | $861K— | ||
| $2.01M-99.9% | $2.45B+283% | $639.81M-25.7% | $861.55M+4,741% | ||
| $2.44M— | —— | -$6.69M-4,980% | $137K+131% | ||
| -$213.77M-2,184% | -$9.36M— | —— | $765.67M+342% | ||
| $14.43M-62.7% | $38.7M+11.3% | $34.78M+3,572% | $947K+167% | ||
| $34.77M+922% | -$4.23M— | —— | $0— | ||
| —— | $9.52M-3.6% | $9.88M— | —— | ||
| —— | —— | —— | —— | ||
| —— | $41.89M+271% | $11.28M+880% | $1.15M— | ||
| —— | $49.95M+199% | $16.72M— | $0— | ||
| $39.89M+50.5% | $26.51M-19.7% | $33.01M— | —— | ||
| $17.72M— | —— | -$17.87M— | —— | ||
| $8.46M-4.3% | $8.84M+26.0% | $7.02M+6.0% | $6.62M+299% | ||
| $43.26M-55.3% | $96.73M+86.7% | $51.82M— | $0— | ||
| $1.53B+35.1% | $1.13B+85.2% | $611.88M+263% | $168.69M— | ||
| $174.69M+161% | $66.96M+432% | $12.59M-13.1% | $14.48M— | ||
| $0-100% | $2.24B+311% | $545.3M-28.2% | $759.18M— | ||
| —— | —— | —— | —— | ||
| $13.01M— | —— | —— | —— | ||
| $7.96M— | —— | —— | —— | ||
| —— | $41.89M+271% | $11.28M+880% | $1.15M— | ||
| -$669.29M-40.9% | -$475.05M-51.8% | -$312.85M-77.3% | -$176.44M-37.9% | ||
| -$669.29M-40.9% | -$475.05M-51.8% | -$312.85M-77.3% | -$176.44M-37.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vaxcyte, Inc. generate?
- Vaxcyte, Inc. (PCVX) generated -$769.9M in operating cash flow over the trailing twelve months.
- What is Vaxcyte, Inc.'s free cash flow?
- After $10.4M of capital expenditures, Vaxcyte, Inc.'s free cash flow was -$780.3M over the trailing twelve months, down 61.9% year over year.
- Where does Vaxcyte, Inc.'s cash flow data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.